AlphAIAlphAI — Financial news for AI agents
proactiveinvestors.comSEP 152 min read$BIVI

BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases

BioVie Inc. reported Phase 2 trial results for bezisterim, showing statistically significant symptom improvements in severe Long COVID patients with high baseline disease burden. The 203-patient trial evaluated 22 clinical outcomes and biomarkers. Subgroup analyses showed significant improvements in fatigue, cognitive impairment, and other symptoms. The company plans further Phase 3 trials to confirm these results. According to the company, bezisterim may become the first therapy for neurologica

Original reporting
proactiveinvestors.com
Published Sep 15, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases — source image
Source · proactiveinvestors.com
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

Phase 2 data reduces clinical risk, likely prompting a price rally pending Phase 3 confirmation.

02

Market read

Positive trial data may attract speculative buying and increase sector momentum.

03

What to watch

Safety profile remains comparable to placebo, but long-term effects are unknown.

Relevance 8/10Novelty 9/10Timing: today

Background

BioVie is a Nasdaq‑listed biotech focused on treatments for post‑viral syndromes.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie reported Phase 2 trial results showing statistically significant improvements in fatigue and cognitive symptoms for high-burden Long COVID patients.

Expected impact

potential short-term upside as investors price in reduced clinical risk

Evidence & confidence

Statistically significant endpoints in a targeted subgroup suggest efficacy, lowering uncertainty before Phase 3.

Market effects

Sector

Long COVID therapeutic space may see increased investor interest.

Regional

U.S. biotech sector could benefit from renewed confidence in early-stage trials.

Global

Potential global demand for effective Long COVID treatments.

Counterpoint

What could challenge this read

Subgroup results may not translate to broader population; Phase 3 could fail.

Key entities

  • Company
    BioVie Inc

    Developer of bezierim for Long COVID.

  • Executive
    Cuong Do

    CEO of BioVie, quoted on trial significance.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 26
$SPCXHighAI 8/10

MARKETS LIVE: Wall Street in the green as investors weigh Anthropic IPO filing

SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.

proactiveinvestors.com3 min
OCT 24
$BIVIMedAI 8/10

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

finanznachrichten.de2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

finance.yahoo.com2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive bezisterim trial results in Parkinson’s

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

investing.com2 min